Extended Lymph Node Dissection May Not Provide a Therapeutic Benefit in Patients with Intermediate-to High-Risk Prostate Cancer Treated with Robotic-Assisted Radical Prostatectomy

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2025 Feb 26

PMID 40002250

Authors

Noriyoshi Miura

Masaki Shimbo

Dai Okawa

Miki Sakamoto

Naoya Sugihara

Takatora Sawada

Shunsuke Haga

Haruna Arai

Keigo Nishida

Osuke Arai

Tomoya Onishi

Ryuta Watanabe

Kenichi Nishimura

Tetsuya Fukumoto

Yuki Miyauchi

Tadahiko Kikugawa

Takato Nishino

Fumiyasu Endo

Kazunori Hattori

Takashi Saika

Affiliations

Soon will be listed here.

Abstract

Background: The therapeutic efficacy of extended lymph node dissection (ePLND) for intermediate- and high-risk (IR/HR) prostate cancer remains controversial. This study evaluated whether PLND improved biochemical recurrence (BCR) rates in patients with prostate cancer undergoing robotic-assisted radical prostatectomy (RARP) using a propensity matching method with cases from two facilities.

Methods: The study included 1002 patients with IR/HR disease who underwent RARP at two facilities with equivalent surgical techniques and hospital size but different ePLND policies for IR/HR between July 2012 and November 2022. We compared perioperative outcomes, complications, and biochemical recurrence-free survival (bRFS) between the centers.

Results: After propensity matching, 221 and 124 cases, each at intermediate and high risk, respectively, were compared. Except for age, preoperative clinicopathological variables did not differ significantly between the matched ePLND and non-PLND groups. A median of 18 lymph nodes were assessed in the dissection group. The 3-year bRFS rates did not differ significantly between ePLND and non-PLND among intermediate-risk and high-risk patients. The dissection group had significantly longer operative times and more complications associated with ePLND, including lower extremity edema, pelvic hematoma, and neuropathy. A multivariable Cox regression analysis performed after propensity adjustment identified initial prostate-specific antigens, pathological tumor stage (high-risk only), and positive surgical margins as independent prognostic factors for bRFS while ePLND was not significant.

Conclusions: These results suggest that ePLND may not be necessary in intermediate- to high-risk PCa patients undergoing RARP, although further study with a longer follow-up is required.

References

Williams S . Surrogate endpoints in early prostate cancer research. Transl Androl Urol. 2018; 7(3):472-482. PMC: 6043744. DOI: 10.21037/tau.2018.05.10. View

Withrow D, DeGroot J, Siemens D, Groome P . Therapeutic value of lymph node dissection at radical prostatectomy: a population-based case-cohort study. BJU Int. 2010; 108(2):209-16. DOI: 10.1111/j.1464-410X.2010.09805.x. View

Mandel P, Kriegmair M, Veleva V, Salomon G, Graefen M, Huland H . The Role of Pelvic Lymph Node Dissection During Radical Prostatectomy in Patients With Gleason 6 Intermediate-risk Prostate Cancer. Urology. 2016; 93:141-6. DOI: 10.1016/j.urology.2016.02.046. View

Touijer K, Vertosick E, Sjoberg D, Liso N, Nalavenkata S, Melao B . Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection. Eur Urol. 2024; 87(2):253-260. DOI: 10.1016/j.eururo.2024.10.006. View

Preisser F, van den Bergh R, Gandaglia G, Ost P, Surcel C, Sooriakumaran P . Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study. J Urol. 2019; 203(2):338-343. DOI: 10.1097/JU.0000000000000504. View

Abdollah F, Gandaglia G, Suardi N, Capitanio U, Salonia A, Nini A . More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer. Eur Urol. 2014; 67(2):212-9. DOI: 10.1016/j.eururo.2014.05.011. View

Fujimoto N, Shiota M, Tomisaki I, Minato A, Yahara K . Reconsideration on Clinical Benefit of Pelvic Lymph Node Dissection during Radical Prostatectomy for Clinically Localized Prostate Cancer. Urol Int. 2019; 103(2):125-136. DOI: 10.1159/000497280. View

Lambertini L, Pacini M, Calvo R, Morgantini L, Cannoletta D, Di Maida F . Extraperitoneal Single Port vs Transperitoneal Multiport Robot assisted radical prostatectomy in frail patients: A propensity score matched comparative analysis. Eur J Surg Oncol. 2024; 50(12):108741. DOI: 10.1016/j.ejso.2024.108741. View

Eastham J, Auffenberg G, Barocas D, Chou R, Crispino T, Davis J . Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up. J Urol. 2022; 208(1):19-25. DOI: 10.1097/JU.0000000000002758. View

10.

Cacciamani G, Maas M, Nassiri N, Ortega D, Gill K, Delloglio P . Impact of Pelvic Lymph Node Dissection and Its Extent on Perioperative Morbidity in Patients Undergoing Radical Prostatectomy for Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis. Eur Urol Oncol. 2021; 4(2):134-149. DOI: 10.1016/j.euo.2021.02.001. View

11.

Preisser F, Bandini M, Marchioni M, Nazzani S, Tian Z, Pompe R . Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. Prostate. 2018; 78(6):469-475. DOI: 10.1002/pros.23491. View

12.

Namiki S, Kawase M, Ebara S, Tatenuma T, Sasaki T, Ikehata Y . Pelvic Lymphadenectomy May Not Improve Biochemical Recurrence-Free Survival in Patients with Prostate Cancer Treated with Robot-Assisted Radical Prostatectomy in Japan (The MSUG94 Group). Cancers (Basel). 2022; 14(23). PMC: 9740735. DOI: 10.3390/cancers14235803. View

13.

Mattei A, Fuechsel F, Dhar N, Warncke S, Thalmann G, Krause T . The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol. 2007; 53(1):118-25. DOI: 10.1016/j.eururo.2007.07.035. View

14.

Chen J, Wang Z, Zhao J, Zhu S, Sun G, Liu J . Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database. Sci Rep. 2019; 9(1):17985. PMC: 6884595. DOI: 10.1038/s41598-019-54261-4. View

15.

Touijer K, Sjoberg D, Benfante N, Laudone V, Ehdaie B, Eastham J . Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial. Eur Urol Oncol. 2021; 4(4):532-539. PMC: 8407534. DOI: 10.1016/j.euo.2021.03.006. View

16.

Colicchia M, Sharma V, Abdollah F, Briganti A, Karnes R . Therapeutic Value of Standard Versus Extended Pelvic Lymph Node Dissection During Radical Prostatectomy for High-Risk Prostate Cancer. Curr Urol Rep. 2017; 18(7):51. DOI: 10.1007/s11934-017-0696-5. View

17.

Joslyn S, Konety B . Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology. 2006; 68(1):121-5. DOI: 10.1016/j.urology.2006.01.055. View

18.

Choo M, Kim M, Ku J, Kwak C, Kim H, Jeong C . Extended versus Standard Pelvic Lymph Node Dissection in Radical Prostatectomy on Oncological and Functional Outcomes: A Systematic Review and Meta-Analysis. Ann Surg Oncol. 2017; 24(7):2047-2054. DOI: 10.1245/s10434-017-5822-6. View

19.

Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012; 48(3):452-8. PMC: 3590441. DOI: 10.1038/bmt.2012.244. View

20.

Moschini M, Fossati N, Abdollah F, Gandaglia G, Cucchiara V, DellOglio P . Determinants of long-term survival of patients with locally advanced prostate cancer: the role of extensive pelvic lymph node dissection. Prostate Cancer Prostatic Dis. 2015; 19(1):63-7. DOI: 10.1038/pcan.2015.51. View